# Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Source: https://onco.cc/trials/nct07044336/  
OnCo record `nct07044336` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Puxitatug samrotecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by AstraZeneca, now recruiting.

## Summary

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) is a phase 3 interventional study registered as NCT07044336 by AstraZeneca, with 800 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-10-15. Interventions recorded: Puxitatug Samrotecan, Doxorubicin, Paclitaxel. Conditions listed: Endometrial Cancer, Malignant Solid Tumour. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07044336
- Phase: 3
- Setting: Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
- Sponsor: AstraZeneca
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT07044336: https://clinicaltrials.gov/study/NCT07044336

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Puxitatug samrotecan](https://onco.cc/drugs/puxitatug-samrotecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07044336.json